Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study

Anthony P Morrison, Heather Law, Lucy Carter, Rachel Sellers, Richard Emsley, Melissa Pyle, Paul French, David Shiers, Alison R Yung, Elizabeth K Murphy, Natasha Holden, Ann Steele, Samantha E Bowe, Jasper Palmier-Claus, Victoria Brooks, Rory Byrne, Linda Davies, Peter M Haddad

Summary
Background Little evidence is available for head-to-head comparisons of psychosocial interventions and pharmacological interventions in psychosis. We aimed to establish whether a randomised controlled trial of cognitive behavioural therapy (CBT) versus antipsychotic drugs versus a combination of both would be feasible in people with psychosis.

Methods We did a single-site, single-blind pilot randomised controlled trial in people with psychosis who used services in National Health Service trusts across Greater Manchester, UK. Eligible participants were aged 16 years or older; met ICD-10 criteria for schizophrenia, schizoaffective disorder, or delusional disorder, or met the entry criteria for an early intervention for psychosis service; were in contact with mental health services, under the care of a consultant psychiatrist; scored at least 4 on delusions or hallucinations items, or at least 5 on suspiciousness, persecution, or grandiosity items on the Positive and Negative Syndrome Scale (PANSS); had capacity to consent; and were help-seeking. Participants were assigned (1:1:1) to antipsychotics, CBT, or antipsychotics plus CBT. Randomisation was done via a secure web-based randomisation system (Sealed Envelope), with randomised permuted blocks of 4 and 6, stratified by gender and first episode status. CBT incorporated up to 26 sessions over 6 months plus up to four booster sessions. Choice and dose of antipsychotic were at the discretion of the treating consultant. Participants were followed up for 1 year. The primary outcome was feasibility (ie, data about recruitment, retention, and acceptability), and the primary efficacy outcome was the PANSS total score (assessed at baseline, 6, 12, 24, and 52 weeks). Non-neurological side-effects were assessed systemically with the Antipsychotic Non-neurological Side Effects Rating Scale. Primary analyses were done by intention to treat; safety analyses were done on an as-treated basis. The study was prospectively registered with ISRCTN, number ISRCTN06022197.

Findings Of 138 patients referred to the study, 75 were recruited and randomly assigned—26 to CBT, 24 to antipsychotics, and 25 to antipsychotics plus CBT. Attrition was low, and retention high, with only four withdrawals across all groups. 40 (78%) of 51 participants allocated to CBT attended six or more sessions. Of the 49 participants randomised to antipsychotics, 11 (22%) were not prescribed a regular antipsychotic. Median duration of total follow-up was 32 weeks (IQR 25–45). PANSS total score was significantly reduced in the combined intervention group compared with the CBT group (−5·65 [95% CI −10·37 to −0·93]; p=0·019). PANSS total scores did not differ significantly between the combined group and the antipsychotics group (−4·52 [95% CI −9·30 to 0·26]; p=0·064) or between the antipsychotics and CBT groups (−1·13 [95% CI −5·81 to 3·55]; p=0·637). Significantly fewer side-effects, as measured with the Antipsychotic Non-neurological Side Effects Rating Scale, were noted in the CBT group than in the antipsychotics (3·22 [95% CI 0·58 to 5·87]; p=0·017) or antipsychotics plus CBT (3·99 [95% CI 1·36 to 6·64]; p=0·003) groups. Only one serious adverse event was thought to be related to the trial (an overdose of three paracetamol tablets in the CBT group).

Interpretation A head-to-head clinical trial of CBT versus antipsychotics versus the combination of both is feasible and safe in people with first-episode psychosis.

Funding National Institute for Health Research.

Copyright © 2018 Elsevier Ltd. All rights reserved.

Introduction Schizophrenia and psychosis are associated with substantial personal, social, and economic costs. High-quality evidence from clinical trials shows that both antipsychotics and cognitive behavioural (CBT) therapy can be helpful to adults with diagnoses of schizophrenia or other psychoses.¹ Many clinical guidelines, therefore, suggest that people with psychosis should be offered both antipsychotics and CBT (as well as family interventions) and should be involved in collaborative decisions about treatment options.¹ However, neither antipsychotics nor CBT are effective for everyone, and
The authors of a meta-analysis showed that 51% of multi-episode patients had at least a minimal response (≥20% reduction in symptoms as measured on the Positive and Negative Syndrome Scale [PANSS] or Brief Psychiatric Rating Scale), and 23% had a good response (≥50% reduction in symptoms), to antipsychotics. By comparison, in first-episode psychosis, 81% of patients had at least a minimal response, and 52% had a good response, to antipsychotics.

The authors of a meta-analysis showed that conclusions about the efficacy of CBT have been exaggerated, given that most large, robust trials have not shown significant effects at end of treatment, and that effect sizes are reduced overall if only studies of high quality are included in meta-analyses.

Antipsychotics are associated with a wide range of adverse effects. Metabolic effects are of particular concern, in view of the increased cardiovascular mortality in people with psychosis compared with the general population. Adverse effects of CBT in psychosis have not been well studied. Potential side-effects, such as stigma and deterioration of mental state, were not detected in clinical trials of CBT for people with psychotic experiences. Rather, CBT resulted in significant reductions in the frequency of these side-effects. However, CBT delivered in the context of a poor therapeutic relationship could be harmful.

Whereas most evidence for the efficacy of CBT for psychosis is from randomised controlled trials in which CBT was provided as an adjunct to antipsychotics (i.e., a combination of both vs antipsychotics alone), preliminary evidence suggests that CBT might be helpful for people with psychosis who are not taking antipsychotics. No data for the relative head-to-head efficacy or acceptability of CBT and antipsychotics in schizophrenia are available. We investigated the feasibility of doing a three-group randomised controlled trial of CBT, antipsychotics, and a combination of CBT and antipsychotics in people with psychosis.

**Methods**

**Study design and participants**

We did a single-blind, randomised, controlled pragmatic pilot and feasibility trial between April 1, 2014, and June 30, 2017 in four specialist mental health National Health Service trusts in Greater Manchester, UK. Eligible participants were aged 16 years or older; met ICD-10 criteria for schizophrenia, schizoaffective disorder, or delusional disorder, or met the entry criteria for an early intervention for psychosis service (operationally defined with the PANSS), because most individuals with early psychosis, but could have different cost–benefit profiles.

**Implications of all the available evidence**

Our preliminary findings seem consistent with guidelines that recommend informed choices and shared decision making about treatment options for early psychosis on the basis of cost–benefit profiles. An adequately powered efficacy and effectiveness trial is now needed to test hypotheses about superiority (e.g., antipsychotics plus CBT vs antipsychotics alone or CBT alone) and non-inferiority (e.g., antipsychotics vs CBT).
دریافت فوری
متن کامل مقاله
امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه ترجمه شده مقالات
پذیرش سفارش ترجمه تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات